Sino Biological
Financials
Estimates*
CNY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 1.6b | 965m | 575m | 646m | 626m | 736m | 878m |
% growth | 783 % | (40 %) | (40 %) | 12 % | (3 %) | 18 % | 19 % |
EBITDA | 1.4b | 889m | 392m | 381m | 248m | 312m | 386m |
% EBITDA margin | 88 % | 92 % | 68 % | 59 % | 40 % | 42 % | 44 % |
Profit | 1.1b | 720m | 303m | 260m | 162m | 208m | 264m |
% profit margin | 71 % | 75 % | 53 % | 40 % | 26 % | 28 % | 30 % |
EV / revenue | - | 24.4x | 22.4x | 16.5x | 11.2x | 9.6x | 8.0x |
EV / EBITDA | - | 26.4x | 32.8x | 27.9x | 28.4x | 22.5x | 18.2x |
R&D budget | 26.1m | 40.1m | 60.1m | 87.4m | - | - | - |
R&D % of revenue | 2 % | 4 % | 10 % | 14 % | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
CNY200m | Series A | ||
CNY100m | Early VC | ||
N/A | CNY5.0b | IPO | |
Total Funding | €37.5m |
Related Content
Recent News about Sino Biological
EditSino Biological Inc. is a biotechnology company specializing in the production and supply of high-quality recombinant proteins, antibodies, and related services for life science research and drug development. The company serves a diverse range of clients, including academic institutions, pharmaceutical companies, and biotech firms, operating in the global biotechnology and pharmaceutical markets. Sino Biological's business model revolves around the development, production, and commercialization of its extensive catalog of biological products, which includes over 6,000 proteins and antibodies. The company generates revenue through the sale of these products and by offering custom services such as protein expression, antibody production, and assay development. Sino Biological has received support from notable organizations, including the Bill & Melinda Gates Foundation, for its contributions to COVID-19 diagnostics and research. The company's innovative solutions and high-quality standards have made it a trusted partner in the scientific community.
Keywords: recombinant proteins, antibodies, life science research, drug development, biotechnology, pharmaceutical, protein expression, antibody production, assay development, COVID-19 diagnostics.